Difference between revisions of "Pegfilgrastim (Neulasta)"
m |
m |
||
| Line 16: | Line 16: | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Granulocyte growth factors]] | [[Category:Granulocyte growth factors]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2002]] | ||
Revision as of 03:22, 9 November 2014
Also known as pegylated GCSF, G-CSF, or granulocyte colony stimulating factor.
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation‚ differentiation, and some end-cell functional activation. The Neulasta formulation involves Filgrastim (Neupogen) being covalently conjugated to monomethoxypolyethylene glycol (mPEG), increasing its half-life.[1][2]
Route: SC
Extravasation: n/a
- "Do not administer Neulasta between 14 days before and 24 hours after administration of cytotoxic chemotherapy."[1]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Pegfilgrastim (Neulasta) patient drug information (Chemocare)[3]
- Pegfilgrastim (Neulasta) patient drug information (UpToDate)[4]